National Institute for Health and Clinical Excellence (NICE)
NICE leads the way to develop a new approach to routinely value and pay for crucial antimicrobials
Blog posted by: James Love-Koh, Scientific Adviser – Science Policy & Research Programme, NICE, 21 November 2022.
James Love-Koh talks about the next steps for the 3-year project to develop a routine framework for evaluating and paying for new antimicrobials.
Paying the right amount for an antimicrobial is an important but challenging task. It should reward clinical value, encourage companies to develop new products and support appropriate use in the real world.
NICE, NHS England and the Department of Health and Social Care are developing a new approach to evaluating antimicrobials that balances these key objectives in a robust and efficient way.
What happened in the pilot antimicrobial evaluations?
In August 2022, we published ground-breaking guidance on two new antimicrobials, cefiderocol and ceftazidime–avibactam. NICE is the first health technology assessment organisation anywhere in the world to attempt to estimate the full value of an antimicrobial – capturing public health benefits that go beyond the direct benefits for the people who receive the drug – to inform payments delinked from sales volume.
This was the culmination of a 3-year project to assess antimicrobials targeting difficult-to-treat drug-resistant pathogens designated as a global priority by the World Health Organisation (WHO) and take account of unmet need in the UK.
The project aimed to address the urgent global need for a supply of new products able to treat types of infections that have become resistant to existing drugs.
By using subscription contracts instead of paying for each dose used, the new NHS payment model aims to incentivise antimicrobial companies to develop new products, while also upholding the important principles of antimicrobial stewardship - an approach that seeks to limit the growth of resistant infections caused by an overuse of antimicrobials.
The pilot evaluations used innovative methods to estimate the health benefits and costs of cefiderocol and ceftazidime–avibactam. In the absence of any relevant randomised or observational studies, they combined laboratory evidence showing how well an antimicrobial slows a pathogen’s growth, with expert opinion and other published evidence on how laboratory outcomes might predict clinical outcomes in order to estimate health benefits and resource-use savings. This allowed the NICE committee to assess the effectiveness of the products in terms of how much they contribute to length and quality of life relative to their cost, as is done for many NICE technology evaluations.
What is happening now?
During the summer, NICE and NHS England held stakeholder workshops to capture the lessons learnt from the antimicrobial pilot – the output from those workshops has been published today.
The next phase of the project is to use that experience to develop a routine framework for evaluating other new antimicrobials and paying for them using the same subscription contract approach. While the pilot evaluations were an important advance in the evaluation of antimicrobials, NICE and its stakeholders agreed that the methods for economic analysis need to be further developed. Combined with the need for improved surveillance data on antimicrobial usage and the resource-intensive nature of the pilot, it was neither practical nor feasible to replicate the approach used in the pilot evaluations on a routine basis.
In its place are plans to adopt a more pragmatic approach to determine the value of the contract payments for qualifying products. We see this as being a clinical points-based scoring system that will allow aspects of value that are unique to antimicrobials to be captured.
We are developing these plans as we continue to work with key stakeholders over the coming months, with an engagement exercise planned in early 2023.
Latest News from
National Institute for Health and Clinical Excellence (NICE)
New life-extending treatment for rare forms of advanced gastroesophageal cancer recommended by NICE24/11/2022 11:15:00
Around 3,000 people could be eligible for a new life-extending combination therapy to treat rare forms of gastroesophageal cancer after NICE published final draft guidance today (24 November 2022)
Fetal balloon procedure is safe for delivering ‘stuck’ babies, NICE says17/11/2022 13:10:00
A balloon inflated underneath a baby’s head after they have become stuck in the pelvis during labour could be used to safely deliver them, NICE has said
Targeted treatment for rare form of aggressive lung cancer gets NICE approval17/11/2022 12:10:00
Mobocertinib recommended as a treatment for a rare and aggressive form of lung cancer
NICE recommends 3 treatments for COVID-19 in draft guidance16/11/2022 15:15:00
Three treatments for COVID have been recommended in draft NICE guidance released today for public consultation.
NICE recommends adapted shoes for people with severe osteoarthritis16/11/2022 11:15:00
People with osteoarthritis who are eligible for knee surgery could be offered specially adapted shoes to help with their painful and stiff knees following a draft recommendation by NICE.
NICE final draft guidance adds further treatment option for triple-negative breast cancer10/11/2022 09:05:00
NICE has recently published final draft guidance which recommends pembrolizumab as an option for people with a type of breast cancer called triple-negative breast cancer.
NICE conditionally recommends digital cognitive behaviour therapies for use in the NHS to help children and young people with symptoms of mild to moderate anxiety04/11/2022 14:15:00
Draft guidance released for consultation today (Friday 4th Nov) states the technologies can be used with support from a mental health professional, while further evidence is generated to check if the benefits they offer are realised in practice.
Towards a new partnership – NICE and the Voluntary and Community Sector04/11/2022 12:33:00
Blog posted by: Victoria Thomas, Head of Public Involvement at NICE, 03 November 2022.
NICE partners with international health technology assessment bodies to boost collaboration on shared opportunities and challenges13/10/2022 11:15:00
SIX health technology assessment (HTA) bodies from three continents are to collaborate on a range of topics that will benefit people accessing healthcare around the world.